Our Pricing

Weight Loss Injections Available Now - In Stock

Published on: June 03, 2026

Finding weight loss injections in stock UK pharmacies has been challenging during recent supply constraints, but Cured Pharmacy maintains consistent availability of Mounjaro, Wegovy, and Saxenda. Our UK-registered clinical team provides free online consultations under three minutes, with transparent upfront pricing and guaranteed genuine UK-licensed medications delivered discreetly to your door.

Why Weight Loss Injections Are More Effective Than Tablets

Injectable GLP-1 receptor agonists like tirzepatide and semaglutide work through fundamentally different mechanisms than oral weight loss medications such as Orlistat. These injections mimic natural gut hormones that regulate appetite, slow gastric emptying, and improve insulin sensitivity—addressing multiple pathways simultaneously rather than simply blocking fat absorption [1].

Clinical trial data demonstrates this superiority clearly. The SURMOUNT-1 trial showed tirzepatide produced average weight reductions of 20.9% over 72 weeks, whilst the STEP-1 trial recorded 14.9% average reduction with semaglutide [1][2]. By comparison, Orlistat typically achieves 5-10% weight loss when combined with dietary changes [3].

The convenience factor also matters significantly. Weekly injections require far less daily adherence than three-times-daily capsules, and patients report fewer gastrointestinal side effects compared to fat-blocking medications. Our superintendent pharmacist Tarun Kumar notes that patient satisfaction scores consistently favour injectable treatments, particularly when proper injection technique is demonstrated during the initial consultation.

Mounjaro, Wegovy, and Saxenda: Understanding Your Options

The three main injectable treatments available through Cured Pharmacy work through related but distinct mechanisms. Mounjaro contains tirzepatide, the UK's first dual GIP/GLP-1 receptor agonist, activating two hormone pathways rather than one [1]. This dual action explains why SURPASS-3 trial participants achieved superior weight reduction compared to single-pathway alternatives.

Wegovy uses semaglutide, a GLP-1 receptor agonist that has been extensively studied across the STEP trial programme. It's administered once weekly via pre-filled pen and has demonstrated consistent efficacy across diverse patient populations [2]. The medication received MHRA approval specifically for weight management in adults with a BMI of 30 or above, or 27 with weight-related comorbidities.

Saxenda contains liraglutide, an earlier-generation GLP-1 medication requiring daily injection rather than weekly administration. Whilst this demands more frequent dosing, some patients prefer the ability to adjust timing around their daily routine, and the lower starting price point makes it accessible for those beginning their weight loss journey.

Which Injectable Treatment Suits Your Needs?

Your UK prescriber will assess multiple factors during your consultation: current BMI, previous weight loss attempts, existing medical conditions, other medications, and personal preferences regarding injection frequency. Patients with type 2 diabetes may find Mounjaro particularly beneficial given its dual mechanism, whilst those prioritising cost-effectiveness might start with Saxenda before transitioning to weekly options.

All three medications require gradual dose escalation to minimise gastrointestinal side effects. Your prescriber will outline the specific titration schedule appropriate for your chosen treatment, ensuring you understand what to expect during the first 8-12 weeks of therapy.

How the Online Consultation Process Works at Cured Pharmacy

Our streamlined consultation takes under three minutes to complete and covers essential medical history, current medications, allergies, and weight loss goals. You'll answer questions designed by our UK-registered clinical team to identify any contraindications or safety concerns specific to GLP-1 medications.

Once submitted, a UK prescriber reviews your assessment—typically within hours during business days. If approved, your prescription is sent electronically to our GPhC-registered pharmacy (registration number 9012511), where our pharmacists dispense genuine UK-licensed medications. We never substitute brands or source from unregulated suppliers.

Delivery occurs in 100% discreet packaging with no external indication of contents. Most patients receive their medication within 2-3 working days via tracked courier. Your first delivery includes comprehensive patient information leaflets, injection technique guides, and direct contact details should you need clinical support during treatment.

What Happens If You're Not Suitable?

Prescription weight loss medications aren't appropriate for everyone. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, and pregnancy or breastfeeding. If your prescriber determines injectable treatments aren't suitable, they'll explain why and suggest alternative approaches, which may include oral medications like Orlistat or referral back to your GP for specialist assessment.

Real-World Results: What Clinical Trials Show

The SURMOUNT-1 trial enrolled 2,539 adults without diabetes, randomising them to tirzepatide (5mg, 10mg, or 15mg) or placebo, all alongside lifestyle interventions. At 72 weeks, participants on the 15mg dose achieved average body weight reduction of 20.9%, with 91% achieving at least 5% weight loss and 57% achieving at least 20% reduction [1].

The STEP trial programme evaluated semaglutide across various populations. STEP-1 demonstrated 14.9% average weight reduction over 68 weeks in adults without diabetes, whilst STEP-2 showed 9.6% reduction in adults with type 2 diabetes—still clinically meaningful but highlighting the additional complexity diabetes introduces [2][4].

These aren't guaranteed outcomes for every patient. Individual results depend on adherence, dietary modifications, physical activity levels, metabolic factors, and concurrent medications. Clinical trials occur under controlled conditions with regular monitoring and support that may differ from real-world settings. However, they provide robust evidence that these medications, when used appropriately, produce substantially greater weight loss than placebo or older treatments.

Managing Side Effects and Maximising Treatment Success

Nausea, diarrhoea, constipation, and reduced appetite are the most commonly reported side effects during the initial weeks of GLP-1 therapy [1][2]. These typically diminish as your body adjusts, particularly when dose escalation follows the recommended gradual schedule. Eating smaller portions, avoiding high-fat meals, and staying well-hydrated significantly reduce gastrointestinal discomfort.

Injection site reactions—mild redness, itching, or swelling—occur in approximately 2-3% of patients but rarely require treatment discontinuation [1]. Rotating injection sites between abdomen, thigh, and upper arm prevents localised irritation. Our pharmacists provide detailed injection technique demonstrations, and you can contact our team anytime if you experience unexpected reactions.

Hypoglycaemia risk increases if you're taking other diabetes medications alongside GLP-1 treatments. Your prescriber will review your current medications and may adjust doses of sulfonylureas or insulin to prevent low blood sugar episodes. Always inform your GP when starting weight loss injections so they can coordinate your overall diabetes management appropriately.

When to Contact Your Prescriber

Seek immediate medical attention if you experience severe abdominal pain (particularly radiating to your back), persistent vomiting, signs of pancreatitis, or allergic reactions. Contact your prescriber if side effects don't improve after the first month, if you're losing weight too rapidly (more than 1-2kg per week), or if you have concerns about continuing treatment. Our clinical team remains available throughout your treatment journey, not just at the point of initial prescription.

Why Cured Pharmacy Guarantees the Lowest Prices in the UK

Transparent upfront pricing distinguishes Cured Pharmacy from competitors who hide costs until after consultation. You'll see exactly what you'll pay before starting your assessment—no surprise fees, no subscription traps, no mandatory follow-up charges. Our business model prioritises volume and patient retention over inflated per-prescription margins.

We source directly from UK-licensed wholesalers and manufacturers, eliminating intermediary markups. Our online-only model avoids the overhead costs of physical premises, allowing us to pass savings directly to patients. When you see competitive UK pricing elsewhere, we're typically £135.00-£135.00 lower for equivalent doses and quantities.

Our lowest price guarantee means if you find genuine UK-licensed weight loss injections cheaper at another GPhC-registered pharmacy, we'll match that price. This applies to like-for-like products—same brand, same dose, same quantity—not grey-market imports or unlicensed compounded versions. We're confident our pricing structure represents the best value available through legitimate UK pharmacy channels.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
4. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Weight loss results vary between individuals and depend on adherence to lifestyle modifications alongside medication. Always consult a qualified healthcare professional before starting any new medication. If you experience severe side effects or medical emergencies, contact NHS 111 or 999 immediately.